Amgen (AMGN)
The desk's stance
On our research list, not on the slate.
What the company does
The biotech blue chip advancing MariTide (maridebart cafraglutide) through the massive MARITIME Phase 3 program — a monthly or less frequent GIPR antagonist / GLP-1 agonist designed to challenge weekly injections on dosing convenience.
In short: Develops innovative biopharmaceutical therapeutics. Category: Commercial Biopharmaceutical Market Leader. Sector: Healthcare, Drug Manufacturers - General.
G-Street Value and Score
G-Street Value: $410.23, computed Oct 18, 2026 (confidence: medium).
How we got there: 70% analyst leg $410.23 (3 analyst targets, credibility- and freshness-weighted, after 8% optimism discount) + 30% GainStreet factor value $438.2 (17.89× fwd EPS anchored to healthcare multiples) — capped at the analyst leg; factors never out-bull the street. 2 analyst targets have no linked source and are shown but not counted.
G-Street Score: 42 out of 100 (Weak).
- Top-line growth & guidance: 0 of 32
- Margin power: 15 of 15
- Revenue visibility & quality: 3 of 11
- Profitability & balance sheet: 15 of 24
- Capital allocation & governance: 5 of 6
- Valuation, sentiment & momentum: 4 of 12
Our current thesis
Updated Oct 17, 2026
The thesis
- Volume gains in Repatha, Evenity, and Uplizna successfully counter biosimilar cliff headwinds.
- MariTide monthly dosing Phase 3 program provides differentiated mega-blockbuster potential in obesity.
- Robust trailing free cash flow of $10.2B comfortably funds deleveraging and dividend payouts.
Risks
- Current $432.49 share price trades substantially above the Street consensus target of $394.98.
- Heavy debt load of $57.3B and 490% debt-to-equity ratio curtail capital allocation flexibility.
- Biosimilar competition against Prolia and mature biologics threatens high-margin legacy cash flows.
What we're watching
- Q3 2026 earnings release on November 3, 2026, targeting $10.06B consensus revenue.
- Phase 3 MariTide head-to-head readout milestones versus semaglutide in obesity.
- Share consolidation and technical support behavior around the $395 consensus level.
Latest
Amgen trades at $432.49 near its 52-week high of $447.03, buoyed by Q2 2026 revenue of $10.05B (+9.5% YoY) and an adjusted EPS beat of $6.29. Rapid expansion in Repatha (+37%), Evenity (+38%), and rare disease assets counters intensifying biosimilar erosion on legacy lines, while Phase 3 MariTide obesity trials drive sentiment. However, the stock trades well above the Street mean price target of $394.98, leaving valuation stretched ahead of Q3 earnings.
Key numbers
As of Oct 16, 2026: market cap $233.8B · revenue growth +9.5% year over year · gross margin 71.9% · net margin 23.0% · forward P/E 17.7 · next earnings Nov 3, 2026.
Analyst price targets
Published analyst targets we could trace to a named source.
- UBS, Buy: $470 target (October 2026). Source: benzinga.com
- RBC Capital, Outperform: $430 target (October 2026). Source: benzinga.com
- Cantor Fitzgerald, Neutral: $440 target (October 2026). Source: benzinga.com
On the Gainz Lab maps
Who it does business with
- Amgen competes with Eli Lilly — MariTide vs Zepbound. A monthly shot against a weekly one: MariTide is Amgen’s high-stakes bid to make extended dosing intervals the competitive wedge.